Global biopharmaceutical company AbbVie has announced plans to invest €40m for the expansion of its medical device manufacturing facility in Ballytivnan, Sligo in Ireland.
Over the next four years, the company said the Ballytivnan manufacturing site expansion will create 50 new jobs focused on devices that deliver its medicines.
This latest investment is supported by Ireland’s Industrial Development Authority (IDA). AbbVie’s investment in Ballytivnan and other broader manufacturing operations in the country has reached a total of more than €134m since 2013.
Known as AbbVie’s ‘centre of excellence’ for medical device manufacturing, precision engineering, plastics moulding and metrology, the Ballytivnan site currently produces drug delivery devices, including a pen-style injector used by patients for a range of auto-immune conditions worldwide.
AbbVie Ballytivnan site director Joe Kumor said: "For more than 40 years, our expert team in Ireland has been committed to serving patients around the world.
"The IDA’s support allows us to build our capabilities and help ensure that patients of AbbVie medicines continue to have access to best-in-class medical devices for their treatment."
As part of its efforts to broaden potential for the company’s local workforce, AbbVie has also partnered with the Institute of Technology, Sligo, Ireland, which is establishing a new medical device-focused education programme on its campus.
In Ireland, AbbVie employs more than 500 people at five different sites, including two manufacturing plants in Sligo and one in Cork. Each of these sites manufactures portions of the company’s 20 leading products.
AbbVie’s global manufacturing network currently includes 13 sites across the US, Europe, Asia and Puerto Rico, as well as strategic partnerships with third-party manufacturers.